Last edition
News about " Ianalumab "
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
Ianalumab | 19/01/2026 | By News Bureau | 180
Novartis Advances Ianalumab Toward Approval for Sjogren's Disease After Phase III Success
Novartis has reported positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjogren's disease.
Ianalumab | 11/08/2025 | By Dineshwori | 203
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy